Spirogen to lead panel debate and make a keynote address at SMi’s 3rd annual ADC Summit this May
LONDON -
(EINPresswire via NewMediaWire) - March 12, 2014 - Philip Howard, PhD Chief Scientific Officer from Spirogen will be leading a panel debate at SMi’s 3rd annual ADC conference taking place in Central London on 19th and 20th May.
Attendees will be invited to discuss creative ways to make the ADC “smart bomb” more intelligent when building an oncology arsenal. The panel debate taking place on 19th May, will be led by Spirogen and will address the latest challenges and improvements to various pieces of the ADC technology puzzle pertaining to antibodies, drugs and the linkers that bond them.Philip Howard will then go onto present an opening keynote address on 20th May. The presentation entitled: The Development of the Pyrrolobenzodiazepine ADC Platform, will focus on antitumor antibodies, Pyrrolobenzodiazepine antibody conjugates and the development of synthetic Pyrrolobenzodiazepine.
Dr M. P. Deonarain, Chief Science Officer from PhotoBiotics Ltd commented,
“London is a world-class hub for biotech innovation, especially in bioconjugation technologies and ADCs. The SMI ADC summit is a great place to showcase our technologies and interact with future potential partners and collaborators to help take your business forward"
A snap shot of confirmed attendees so far include:
Ablynx
Algeta AS
Carbogen AMCIS
Genentech
ImmunoGen
Imperial College London
Medimmune Inc
Mersana Therapeutics
Pfizer
Philochem A G
Photobiotics
Progenics Pharmaceuticals Inc
Regeneron
SafeBridge Europe, Limited
Spirogen
Sutro Biopharma, Inc.
Synthon BV
University of Oxford
Viventia Bio Inc.
For further details, a conference brochure or to register onto the event, visit www.adcsummit.com
ADC SUMMIT
19th & 20th May 2014
Holiday Inn Regents Park Hotel, London UK
Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
